Friday, June 2, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

RFI – Advanced Development of Multiplex Diagnostics

by Global Biodefense Staff
February 7, 2014

The National Institute of Allergy and Infectious Diseases (NIAID) is seeking information from diagnostics product developers interested in supporting the advanced development of integrated clinical multiplex diagnostic technologies to detect emerging and re-emerging infectious diseases.

Targets include NIAID Priority Pathogens and other common medically-important pathogens directly from a blood sample, without a blood culture step. The primary focus of the RFI is to gather information about the current product development status of the integrated instrument and potential multiplex diagnostic test.

Areas of greatest interest include multiplexed diagnostics designed for use in a primary healthcare setting; composed of a single operating unit capable of accepting a clinical sample, or a cartridge-based operating unit; and having automated sample prep and reporting capabilities.

NIAID invites organizations to submit a white paper describing their research efforts towards developing an integrated clinical sample-to-answer multiplex diagnostic product to detect Bacillus anthracis, Yersinia pestis, Francisella tularensis and a minimum of two commonly diagnosed prevalent pathogens with similar early symptoms as the three required biothreat pathogens (fever, malaise, flu-like symptoms, etc.).

Further details are available under Solicitation Number: NIH-AI-2014009. The response deadline if February 24, 2014.

Tags: AnthraxF. tularensisMultiplexPOC DiagnosticsRFIY. pestis

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
New Material Helps Train First Responders on Biothreats
Biodetection

New Material Helps Train First Responders on Biothreats

January 4, 2023
Researcher holds a pipette
Biodetection

These Nanotech Bubbles Burst When They Detect Viruses in the Air

October 25, 2022
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC